PURPOSE: Time to progression (TTP), overall survival, and quality of life (QL) were compared in patients with hormone-resistant prostate cancer (HRPC) treated with prednisone (5 mg orally, four times ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results